tiprankstipranks
Advertisement
Advertisement
ProQR Therapeutics price target lowered to $3 from $4 at Chardan
PremiumThe FlyProQR Therapeutics price target lowered to $3 from $4 at Chardan
26d ago
ProQR Reports Positive Phase 1 Data Validating Axiomer RNA Editing Platform
Premium
Company Announcements
ProQR Reports Positive Phase 1 Data Validating Axiomer RNA Editing Platform
27d ago
ProQR Therapeutics prices 27.62M shares at $1.81 in registered direct offering
Premium
The Fly
ProQR Therapeutics prices 27.62M shares at $1.81 in registered direct offering
27d ago
ProQR Posts Wider Q1 2026 Loss but Maintains Strong Cash Position
PremiumCompany AnnouncementsProQR Posts Wider Q1 2026 Loss but Maintains Strong Cash Position
2M ago
ProQR Sets June 2, 2026 Date for Annual General Meeting of Shareholders
Premium
Company Announcements
ProQR Sets June 2, 2026 Date for Annual General Meeting of Shareholders
3M ago
ProQR Nominates Boehringer Ingelheim CMO Lykke Hinsch Gylvin to Board to Support Next Growth Phase
Premium
Company Announcements
ProQR Nominates Boehringer Ingelheim CMO Lykke Hinsch Gylvin to Board to Support Next Growth Phase
3M ago
Oppenheimer Predicts Up to ~560% Rally for These 2 ‘Strong Buy’ Stocks
PremiumStock Analysis & IdeasOppenheimer Predicts Up to ~560% Rally for These 2 ‘Strong Buy’ Stocks
4M ago
ProQR Sets April 8 Virtual Investor Event to Spotlight Axiomer RNA Editing Pipeline
Premium
Company Announcements
ProQR Sets April 8 Virtual Investor Event to Spotlight Axiomer RNA Editing Pipeline
4M ago
ProQR Therapeutics Faces Heightened Activist Investor Pressure and Governance Uncertainty
Premium
Company Announcements
ProQR Therapeutics Faces Heightened Activist Investor Pressure and Governance Uncertainty
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100